DK0874845T3 - Pyrido[2,3-b]pyrazinderivater - Google Patents

Pyrido[2,3-b]pyrazinderivater

Info

Publication number
DK0874845T3
DK0874845T3 DK96941882T DK96941882T DK0874845T3 DK 0874845 T3 DK0874845 T3 DK 0874845T3 DK 96941882 T DK96941882 T DK 96941882T DK 96941882 T DK96941882 T DK 96941882T DK 0874845 T3 DK0874845 T3 DK 0874845T3
Authority
DK
Denmark
Prior art keywords
alkenyl
pyridyl
phenyl
amino
alkenoyl
Prior art date
Application number
DK96941882T
Other languages
Danish (da)
English (en)
Inventor
Norihiko Shimazaki
Akihiko Sawada
Shinya Watanabe
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0874845T3 publication Critical patent/DK0874845T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
DK96941882T 1995-12-27 1996-12-13 Pyrido[2,3-b]pyrazinderivater DK0874845T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526558.3A GB9526558D0 (en) 1995-12-27 1995-12-27 Heterobicyclic derivatives
PCT/JP1996/003666 WO1997024355A1 (fr) 1995-12-27 1996-12-13 Derives de pyrido(2,3-b)pyrazine

Publications (1)

Publication Number Publication Date
DK0874845T3 true DK0874845T3 (da) 2002-07-01

Family

ID=10786098

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941882T DK0874845T3 (da) 1995-12-27 1996-12-13 Pyrido[2,3-b]pyrazinderivater

Country Status (18)

Country Link
US (1) US6117875A (fr)
EP (1) EP0874845B1 (fr)
JP (1) JP2000502699A (fr)
KR (1) KR19990072053A (fr)
CN (1) CN1066732C (fr)
AT (1) ATE214067T1 (fr)
AU (1) AU720301B2 (fr)
CA (1) CA2241690A1 (fr)
DE (1) DE69619702T2 (fr)
DK (1) DK0874845T3 (fr)
EA (1) EA001324B1 (fr)
ES (1) ES2170286T3 (fr)
GB (1) GB9526558D0 (fr)
HU (1) HUP9901038A3 (fr)
IL (1) IL124673A (fr)
MX (1) MX9805129A (fr)
PT (1) PT874845E (fr)
WO (1) WO1997024355A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
NZ519981A (en) 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
CN1307159C (zh) 2000-05-31 2007-03-28 参天制药株式会社 TNF－α生成抑制剂
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN100572381C (zh) * 2002-11-06 2009-12-23 Aska制药株式会社 吡唑并二氮杂萘衍生物
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1729771B1 (fr) 2004-03-22 2009-10-14 Eli Lilly & Company Derives de pyridyle et leur utilisation en tant qu'antagonistes du recepteur de mglu5
CA2603830A1 (fr) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc Pyridine [2,3-b] pyrazinones
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
MX2010009577A (es) * 2008-03-05 2010-09-24 Merck Patent Gmbh Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
WO2010096426A2 (fr) * 2009-02-20 2010-08-26 Emory University Composés, compositions, procédés de synthèse et procédés de traitement
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
JP2022532178A (ja) * 2019-05-10 2022-07-13 上海海雁医薬科技有限公司 置換フェニルプロペニルピリジン誘導体、その調製方法及びその医学的使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (fr) * 1978-08-15 1980-03-19 FISONS plc Dérivés de la pyridopyrazine et de la quinoxaline, procédés pour leur préparation, et compositions pharmaceutiques les contenant
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives

Also Published As

Publication number Publication date
IL124673A (en) 2002-07-25
CN1205702A (zh) 1999-01-20
WO1997024355A1 (fr) 1997-07-10
ES2170286T3 (es) 2002-08-01
JP2000502699A (ja) 2000-03-07
EP0874845A1 (fr) 1998-11-04
CA2241690A1 (fr) 1997-07-10
DE69619702D1 (de) 2002-04-11
DE69619702T2 (de) 2002-08-14
KR19990072053A (ko) 1999-09-27
GB9526558D0 (en) 1996-02-28
HUP9901038A3 (en) 2000-04-28
EP0874845B1 (fr) 2002-03-06
EA199800599A1 (ru) 1998-12-24
MX9805129A (es) 1998-10-31
AU1111297A (en) 1997-07-28
HUP9901038A2 (hu) 1999-07-28
US6117875A (en) 2000-09-12
CN1066732C (zh) 2001-06-06
PT874845E (pt) 2002-08-30
IL124673A0 (en) 1998-12-06
EA001324B1 (ru) 2001-02-26
AU720301B2 (en) 2000-05-25
ATE214067T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
ATE214067T1 (de) Pyrido (2,3-b) pyrazinderivate
AU4954097A (en) 2-pyrimidineamine derivatives and processes for their preparation
EP0349949A3 (fr) Derivés de benzodiazépine
AU7453498A (en) Sulfonamide derivatives, their production and use
GR3034542T3 (en) 4,5-diaryloxazole derivatives
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
KR960701055A (ko) 인터로이킨-1 및 종양 괴사 인자 억제 활성을 지닌 피라졸로트리아진 (pyrazol itriazines with interleukin-1 and tumour necrosis factor in-hibitory actvity)
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
IE901799L (en) Anti inflammatory aminophenol derivatives
CA2176935A1 (fr) Arylpiperazines derivees d'indole comme ligands pour les recepteurs 5 ht1-like 5 ht1b et 5 ht1d
EP1140900A4 (fr) Composes pyrazole et utilisation de tels composes
AU1556997A (en) Chinoline and benzimidazole derivatives as bradykinin agonists
DE69633943D1 (de) Morphine derivate mit analgetischen eigenschaften
FI951555A0 (fi) 5H,10H-imidatso[1,2-a]indeno[1,2-e]pyratsin-4-onijohdannaiset, niiden valmistus ja niitä sisältävät lääkkeet
NZ332310A (en) Optionally condensed pyrimidine substituted hexahydro-pyrido[4,3-b]indole derivatives and medicaments
EP1110960A4 (fr) Agents induisant l'apoptose
DE69613385D1 (de) Cephemverbindungen
NO953913D0 (no) Perhydroisoindolderivater, deres fremstilling samt farmasöytiske preparater inneholdende derivatene